Morinaga Milk Expands Lactoferrin Production Capacity in German Subsidiary “MILEI GmbH”
28.10.2020 08:52:00 EET | Business Wire | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO: 2264) (hereafter, “Morinaga Milk”) hereby announces that its subsidiary MILEI GmbH (hereafter, “MILEI”), which has the largest share* of the global market in terms of production volume of the functional ingredient lactoferrin, will increase more than double its production capacity with the aim to enhance its lactoferrin production.
* According to data for 2019 released by Absolute Reports
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006307/en/
Powdered lactoferrin (Photo: Morinaga Milk)
1. Overview
(1) Location: Kemptener Strasse 91, 88299 Leutkirch, Germany
(2) Product manufactured: Lactoferrin
(3) Total investment: EUR 15,000,000 (approx. JPY 1.8 billion*) * Assuming an exchange rate of 120 yen to one euro
(4) Production capacity: Approx. 170 tons (more than double that of fiscal 2019)
(5) Launch of operations: April 2021 (planned)
2. Background and purpose
As a functional ingredient for infant formula, supplements and other foods, the demand for lactoferrin has been growing particularly in Western countries and Asia.
Considering the increasing attention towards health and nutrition, the demand for lactoferrin as a functional ingredient with health value is expected to grow over the long term globally.
Morinaga Milk Group considers lactoferrin as an important functional ingredient to support people’s health and nutrition worldwide and has been conducting fundamental research and seeking commercial applications for over six decades.
Morinaga Milk Group is aiming to increase the sales of its own lactoferrin-related products with expanding production capacity in MILEI, and will flexibly respond to the long-term increasing demand of lactoferrin.
Having the largest production share of lactoferrin, Morinaga Milk Group will increase the production of MILEI and contribute to the well-being of people.
3. Effect on financial results
The investment will not affect financial results for the fiscal year ending March 31, 2021.
[Reference information]
MILEI GmbH
MILEI is based in the southern German city of Leutkirch, where its production facilities are located.
Founded in 1972, MILEI has a history of almost five decades since its start of production in 1975. MILEI offers lactoferrin, whey protein concentrate, lactose and other dairy ingredients mainly in Europe and Asia. Many companies, including global food manufacturers, use MILEI’s ingredients for infant formula, sports nutrition and others. Under the global strategy of Morinaga Milk, MILEI plays an important role supporting production and sales of ingredients for infant formula, supplements and others.
Lactoferrin
Present in most exocrine secretions such as breast milk and saliva of humans and other mammals, lactoferrin is a component with a wide range of physiological functions. The high amount of lactoferrin found in human breast milk, especially in colostrum, is considered to offer important and protective benefits to newborns.
Discovered by Danish scientists in 1939, lactoferrin as a remarkable functional ingredient, has been intensively researched by scientists worldwide, as shown by the increasing number of the studies in the graph (Figure 1). Paying high attention to the fact that lactoferrin is highly abundant in colostrum, Morinaga Milk has been focusing its research efforts on lactoferrin over the long term to develop infant formula that closely resembles breast milk. Since its initial publication of a research paper on lactoferrin in 1963, Morinaga Milk has been reporting its benefits through academic forums, conferences and publications.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027006307/en/
Contact information
International Division, Morinaga Milk Industry Co., Ltd.
Yoshihiko Ushida
Tamami Shibata
TEL: +81-3-3798-0152
E-mail: interntl@morinagamilk.co.jp
https://www.morinagamilk.co.jp/english/
https://www.milei.de (MILEI GmbH Website)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 23:00:00 EEST | Press release
Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas GulfLink will immediately begin construction of its deepwater crude oil export terminal, unlock
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom